Drug intelligence / Profile preview

EQ-8

Development stage: Preclinical
Lead developer: AxoProtego Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**EQ-8** is a preclinical **small molecule** neuroprotective candidate being developed by **AxoProteGo Therapeutics** for **multiple sclerosis** and **Parkinson's disease**. The compound is described as an **ethoxyquin-derived quinoline antioxidant** designed to improve **water solubility**, **oral bioavailability**, and **blood-brain barrier penetration** relative to ethoxyquin. Its proposed mechanism is **modulation of heat shock protein 90 chaperone activity**, with the therapeutic rationale of reducing neurodegenerative injury and promoting neuroprotection in central nervous system disease. AxoProteGo Therapeutics holds rights to ethoxyquin and related derivatives through a worldwide license from Johns Hopkins.

Other names: ethoxyquin derivative

Targets

HSP90 (Heat shock protein 90 chaperone complex)

Beyond the preview

Go deeper on EQ-8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EQ-8.

Explore the full profile